0
A recent study confirmed that the Ozempic and other GLP-1 class medicines can reduce alcohol consumption and the related wishes.
Ozepic can help reduce alcohol consumption, study. Image: kk Stock/shutterstock
In a clinical trial with 48 people with signs of alcohol use disorder, those who took semaglutida For nine weeks they drank 40% less alcohol and reported a significant reduction in the desire for alcohol compared to those who took placebo.
This effect suggests that, in addition to controlling appetite, GLP-1 medications can help treat alcohol use disorder (AUD).
Study discoveries
- The study, published in the newspaper indicated that semaglutado can be more effective than traditional AUD treatments, such as the naltrexone.
- Although the study has been small and short, the results raise the possibility of GLP-1 drugs playing an important role in reducing excessive alcohol consumption, especially if the results are confirmed in larger tests.
- GLP-1 medications, such as Ozempic and Wegovy (for obesity), act in the brain and intestine, and can reduce the desire for alcohol and the gratifying effects of consumption.
- In the study, participants who used Semaglutida also lost about 5% of body weight, but there were no changes in the number of days a week they drank.
- The reduction in consumption was more evident when they consumed alcohol.
Although more studies are still needed to completely understand the mechanisms behind this action, the potential of GLP-1 drugs to treat AUD is promising.
Additional tests are underway to further investigate these effects, including a NIH study.
However, pharmaceutical companies have not yet actively sought the approval of the FDA for the use of these drugs in the Treatment of alcohol use disorderfocusing mainly on other indications such as cardiovascular and kidney diseases.
